Home About us Current issue Ahead of Print Back issues Submission Instructions Advertise Contact Login   

Search Article 
Advanced search 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 1099 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

ARTICLES Table of Contents   
Year : 2005  |  Volume : 16  |  Issue : 4  |  Page : 506-513
Current Use and Future Trends in Induction Therapy

University of California, San Francisco, California, USA

Correspondence Address:
Flavio Vincenti
University of California, San Francisco, 505 Parnassus Avenue, Room M884, Campus Box 0780, San Francisco, CA 94143-0780
Login to access the Email id

Source of Support: None, Conflict of Interest: None

PMID: 18202505

Rights and PermissionsRights and Permissions

Induction therapy has been utilized since the late 70s to reorient the immune system at the time of antigen presentation, decrease acute rejection and improve long-term graft survival. Currently, over 70% of patients undergoing kidney transplantation receive induction therapy. The current agents include OKT3, polyclonal antilymphocyte agents (Thymoglobulin being most frequently used), the anti-interleukin-2 receptor monoclonal antibodies daclizumab and basiliximab and Campath 1H. The current biologic agents are used for short-term therapy although their biologic effects may be prolonged. The next generation of induction agents is being developed for chronic use in calcineurin inhibitor­free and/or steroid-free regimens. These new biologic agents will be developed to simplify immunosuppression regimens, improve compliance and minimize long term toxicities.

Print this article  Email this article

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded651    
    Comments [Add]    

Recommend this journal